Enzymatic Treatment for Postoperative Nasal Fibrosis After Rhinoplasty
A Fixed-Sequence Crossover Clinical Trial Evaluating Enzymatic Treatment for Mild-to-Moderate Postoperative Nasal Fibrosis After Rhinoplasty
This single-arm, fixed-sequence clinical trial will evaluate an enzymatic preparation for mild-to-moderate postoperative fibrosis of the nasal soft-tissue envelope after rhinoplasty. Each participant will first receive 3 mL of sterile saline injected into the affected nasal area. Two weeks later, clinical assessment and high-resolution nasal ultrasonography, including elastography, will be performed, after which the participant will receive a 3-mL enzymatic preparation in the same affected area. A second clinical assessment and ultrasound examination will be performed 2 weeks after the enzymatic treatment. Changes during the saline and enzymatic treatment periods will be compared within each participant.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Adults with mild-to-moderate fibrosis of the nasal soft-tissue envelope after rhinoplasty will receive two interventions in a fixed sequence. During Period 1, 3 mL of sterile saline will be injected into the affected nasal area. At 2 weeks, clinical assessment and high-resolution nasal ultrasonography, including elastography, will be performed. The enzymatic preparation will then be injected into the same affected area. It will contain recombinant lipase, collagenase, and hyaluronidase and will be prepared by adding 1.5 mL of high-molecular-weight hyaluronic acid, waiting approximately 5 minutes, and then adding 1.5 mL of sterile saline, for a total volume of 3 mL. Two weeks after the enzymatic treatment, clinical assessment and ultrasound, including elastography, will be repeated. All participants will receive saline first and the enzymatic preparation second.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Minyor Avellaneda, MD, Plastic surgeon
- Phone Number: +57 (320) 767 4006
- Email: contacto@nuarabelleza.com
Study Locations
-
-
Bogota D.C.
-
Bogotá, Bogota D.C., Colombia, 110121
- Recruiting
- NUARA
-
Contact:
- Minyor Avellaneda, MD, Plastic surgeon
- Phone Number: +57 (320) 767 4006
- Email: contacto@nuarabelleza.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adults aged 18 years or older. History of rhinoplasty performed at least 3 months before enrollment. Complete healing of the surgical wounds at enrollment. Mild-to-moderate fibrosis of the nasal soft-tissue envelope in an identifiable affected area, diagnosed by clinical examination and documented by baseline high-resolution nasal ultrasonography.
Ability and willingness to provide written informed consent. Ability and willingness to complete the study assessments and follow-up visits.
Exclusion Criteria:
- Severe nasal fibrosis or deformity requiring surgical correction or urgent treatment.
Active infection, open wound, ulceration, or tissue necrosis in the proposed injection area.
Previous injection or other treatment specifically for nasal fibrosis Known hypersensitivity to any component of the enzymatic preparation or to sterile saline.
Pregnancy or breastfeeding. Any medical condition that, in the investigator's judgment, makes study injections unsafe or prevents reliable completion of study assessments.
Inability to provide informed consent or comply with study procedures.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Fixed Sequence: Saline Followed by Enzymatic Treatment
All participants will first receive 3 mL of sterile saline injected into the affected nasal area. Two weeks later, after clinical assessment and ultrasound, they will receive 3 mL of a recombinant enzymatic preparation containing lipase, collagenase, and hyaluronidase, injected into the same affected area. The enzymatic preparation will be reconstituted with 1.5 mL of high-molecular-weight hyaluronic acid, followed approximately 5 minutes later by 1.5 mL of sterile saline. Final ultrasound and clinical assessment will be performed 2 weeks after the enzymatic treatment. |
A total volume of 3 mL of sterile saline injected into the affected nasal area once at the beginning of the study. A total volume of 3 mL containing recombinant lipase, collagenase, and hyaluronidase, injected into the affected nasal area 2 weeks after the saline injection. The preparation will be made by adding 1.5 mL of high-molecular-weight hyaluronic acid, waiting approximately 5 minutes, and then adding 1.5 mL of sterile saline. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Difference in change in nasal soft-tissue thickness between the saline and enzymatic treatment periods
Time Frame: Baseline, 2 weeks after saline treatment and before enzymatic treatment, and 2 weeks after enzymatic treatment
|
High-resolution nasal ultrasonography will be used to measure soft-tissue thickness at the prespecified affected area. Measurements will be obtained before saline treatment, 2 weeks after saline treatment and before enzymatic treatment, and 2 weeks after enzymatic treatment. The change during the enzymatic period will be compared with the change during the saline period within each participant. Thickness will be recorded in millimeters. |
Baseline, 2 weeks after saline treatment and before enzymatic treatment, and 2 weeks after enzymatic treatment
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Difference in change in nasal soft-tissue elastography measurements between treatment
Time Frame: Baseline, 2 weeks after saline treatment and before enzymatic treatment, and 2 weeks after enzymatic treatment
|
Elastography will be recorded at the prespecified affected area at baseline, 2 weeks after saline treatment and before enzymatic treatment, and 2 weeks after enzymatic treatment. The change during the enzymatic period will be compared with the change during the saline period within each participant. The elastography parameter and units reported by the ultrasound system will be specified in the study protocol. |
Baseline, 2 weeks after saline treatment and before enzymatic treatment, and 2 weeks after enzymatic treatment
|
|
Change in structural characteristics of the nasal soft-tissue envelope
Time Frame: Baseline, 2 weeks after saline treatment and before enzymatic treatment, and 2 weeks after enzymatic treatment
|
Structural characteristics of the previously operated nasal soft-tissue envelope at the affected area will be assessed by high-resolution nasal ultrasonography at each study assessment. |
Baseline, 2 weeks after saline treatment and before enzymatic treatment, and 2 weeks after enzymatic treatment
|
|
Treatment-emergent adverse events
Time Frame: Baseline, 2 weeks after saline treatment and before enzymatic treatment, and 2 weeks after enzymatic treatment
|
Adverse events reported or observed after saline and enzymatic injections, including local pain, swelling, erythema, skin changes, infection, tissue injury, or other adverse events. |
Baseline, 2 weeks after saline treatment and before enzymatic treatment, and 2 weeks after enzymatic treatment
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
General Publications
- Nascimento NS, Torres-Obreque KM, Oliveira CA, Rabelo J, Baby AR, Long PF, Young AR, Rangel-Yagui CO. Enzymes for dermatological use. Exp Dermatol. 2024 Jan;33(1):e15008. doi: 10.1111/exd.15008.
- Shekhter AB, Balakireva AV, Kuznetsova NV, Vukolova MN, Litvitsky PF, Zamyatnin AA Jr. Collagenolytic Enzymes and their Applications in Biomedicine. Curr Med Chem. 2019;26(3):487-505. doi: 10.2174/0929867324666171006124236.
- Menick FJ, Salibian A. Primary intranasal lining injury cause, deformities, and treatment plan. Plast Reconstr Surg. 2014 Nov;134(5):1045-1056. doi: 10.1097/PRS.0000000000000694.
- Kryczka J, Boncela J. Proteases Revisited: Roles and Therapeutic Implications in Fibrosis. Mediators Inflamm. 2017;2017:2570154. doi: 10.1155/2017/2570154. Epub 2017 May 31.
- Afratis NA, Klepfish M, Karamanos NK, Sagi I. The apparent competitive action of ECM proteases and cross-linking enzymes during fibrosis: Applications to drug discovery. Adv Drug Deliv Rev. 2018 Apr;129:4-15. doi: 10.1016/j.addr.2018.03.004. Epub 2018 Apr 5.
- Sharif-Askary B, Carlson AR, Van Noord MG, Marcus JR. Incidence of Postoperative Adverse Events after Rhinoplasty: A Systematic Review. Plast Reconstr Surg. 2020 Mar;145(3):669-684. doi: 10.1097/PRS.0000000000006561.
- Hacker S, Pollock J, Gubisch W, Haack S. Differences between Primary and Revision Rhinoplasty: Indications, Techniques, Grafts, and Outcomes. Plast Reconstr Surg. 2021 Sep 1;148(3):532-541. doi: 10.1097/PRS.0000000000008216.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 027
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
non considered in the patient informed consent
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.